Search
Southern Yuan Biotech has successfully completed a Series A funding round, raising tens of millions of yuan. This investment was led by FJ Capital, with participation from Hetang Venture Capital. The proceeds from this funding will be dedicated primarily to catalyzing the registration and industrialization of the company's flagship product, the Hemoadhican® (HD) series of medical devices, in both China and the United States. The HD series leverages proprietary biopolymer synthetic hemostasis technology, offering second-level hemostasis, robust bioadhesion, and complete biodegradability, making it ideal for both open and minimally invasive surgical procedures. Southern Yuan Biotech aims to expedite global multicenter clinical trials and develop additional hemostatic products tailored for battlefield rescue missions and surgical operations.
-
C114 Communication Network -
Communication Home
